A next-generation probiotic: Akkermansia muciniphila ameliorates chronic stress–induced depressive-like behavior in mice by regulating gut microbiota and metabolites

• Published in: Applied microbiology and biotechnology Vol. 105; no. 21-22; pp. 8411 - 8426
• Main Authors: Ding, Yang, Bu, Fan, Chen, Tuo, Shi, Guoping, Yuan, Xiaomin, Feng, Zeyu, Duan, Zhenglan, Wang, Rong, Zhang, Sumin, Wang, Qiong, Zhou, Jinyong, Chen, Yugen
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-11-2021; Springer; Springer Nature B.V
• Subjects: Abnormalities; Akkermansia muciniphila; Anaerobic bacteria; Analysis; Antidepressants; Applied Microbial and Cell Physiology; Biomarkers; Biomedical and Life Sciences; Biotechnology; Brain-derived neurotrophic factor; Cecum; Correlation coefficient; Correlation coefficients; Corticosterone; Depression, Mental; Dopamine; Gene sequencing; Genetic aspects; Histidine; Identification and classification; Intestinal microflora; Life Sciences; Mental depression; Mental health; Metabolites; Metabolomics; Methods; Microbial Genetics and Genomics; Microbiology; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Neurotransmitters; Phenotypes; Probiotics; RNA sequencing; rRNA 16S; Signs and symptoms; Stress; China; Gut microbiota; Depression; Stress; Untargeted metabolomics
• ISSN: 0175-7598; 1432-0614
• DOI: 10.1007/s00253-021-11622-2

Major depressive disorder (MDD) is a neurasthenic disease, which is the second-largest burden of disease globally. Increasing studies have revealed that depression is associated with abnormalities in gut microbiota and metabolites. Several species of bacteria have been classified as psychobiotics, which confer mental health benefits through interactions with commensal gut microbiota. Therefore, it is essential to identify new psychobiotics and elucidate their mechanisms in the treatment of depression. This study aims to evaluate the antidepressant effect of
Akkermansia muciniphila
(AKK) in a mouse model of depression induced by chronic restraint stress (CRS). C57BL/6 male mice were divided into three groups: mice subjected to CRS, mice not subjected to CRS, and mice treated with AKK for 3 weeks. Behavioral tests were performed, and hormone, neurotransmitter, and brain-derived neurotrophic factor (BDNF) levels were measured. Cecal microbiota was analyzed using 16S rRNA gene sequencing, and serum metabolites were detected using untargeted metabolomics. In addition, correlations between altered gut microbiota and metabolites with significant variations in serum associated with AKK ameliorating depression were analyzed using Pearson’s correlation coefficient. The results revealed that AKK significantly ameliorated depressive-like behavior and restored abnormal variations in depression-related molecular (corticosterone, dopamine, and BDNF). Moreover, AKK altered chronic stress–induced gut microbial abnormalities. Untargeted metabolomics analysis revealed 23 potential biomarkers in serum that could be associated with the mechanisms underlying CRS-induced depression and the therapeutic effects of AKK. Pearson’s correlation coefficient analysis revealed that AKK predominantly upregulated β-alanyl-3-methyl-
l
-histidine and edaravone to relieve depression. Furthermore, β-alanyl-3-methyl-
l
-histidine and edaravone exhibited the antidepressant phenotype in mice subjected to CRS. In conclusion, the study demonstrated that AKK ameliorates chronic stress–induced depressive symptoms in mice by regulating gut microbiota and metabolites.
Key points
• AKK reduces depressive-like behaviors induced by chronic stress.
• AKK regulates the gut microbial structure and metabolomics of serum under the chronic stress.
• Antidepressant effect of AKK correlates with the increase of β-alanyl-3-methyl-l-histidine and edaravone.